Related Experiment Video
Updated: Aug 1, 2026
Methods to Inhibit Bacterial Pyomelanin Production and Determine the Corresponding Increase in Sensitivity to Oxidative Stress
Published on: August 31, 2015
Therapeutic experience with netilmicin
Abstract:
Netilmicin, a new aminoglycoside antibiotic, was used to treat 19 patients with urinary tract infection and 5 with systemic infection. The causal organisms were Escherichia coli (in 2), Klebsiella pneumoniae (in 4), Serratia marcescens (in 12) and Pseudomonas aeruginosa (in 7); 1 patient was infected with two of these organisms. All the isolates of causal organisms except one of Serratia were initially sensitive to netilmicin but many were resistant to other aminoglycosides. Sixteen of the urinary tract infections responded to netilmicin therapy, although relapse occurred in three patients. Two of the three patients with musculoskeletal infection responded to combined therapy with surgery and netilmicin; the other patient responded to the same regimen but with carbenicillin added. Netilmicin cured pneumonia in one patient but failed in the other patient with pneumonia, who had leukemia. Superinfection occurred in five patients with urinary tract infection. Adverse reactions to netilmicin were minor. Netilmicin may prove to be a useful agent, particularly for infections due to multiresistant Klebsiella or Serratia, or when prolonged aminoglycoside therapy is required.
Insights
Netilmicin, a new aminoglycoside antibiotic, effectively treated many infections, including those resistant to other drugs. It showed promise for complex cases, though some relapses and superinfections occurred.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Aminoglycoside antibiotics are crucial for treating serious bacterial infections.
- Emerging resistance to existing aminoglycosides necessitates the development of new agents.
- Netilmicin represents a novel aminoglycoside with potential activity against resistant pathogens.
Observation:
- A study evaluated netilmicin in 24 patients with urinary tract or systemic infections.
- Common pathogens included Serratia marcescens, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli.
- Many isolates were resistant to other aminoglycosides but sensitive to netilmicin.
Findings:
- Netilmicin demonstrated efficacy in 16 of 19 urinary tract infections, with 3 relapses.
- Musculoskeletal infections showed positive responses to netilmicin combined with surgery, with or without carbenicillin.
- Pneumonia treatment was successful in one patient but failed in an immunocompromised patient with leukemia.
- Superinfections occurred in 5 patients with urinary tract infections, and adverse reactions were minor.
Implications:
- Netilmicin shows potential as a valuable therapeutic option, especially for infections caused by multidrug-resistant Klebsiella or Serratia.
- Its utility may extend to situations requiring extended aminoglycoside therapy.
- Further research is warranted to fully define netilmicin's role in combating challenging bacterial infections.
More Related Videos
11:32Real-Time, High-Throughput Microscopic Quantification of Human Neutrophil Extracellular Trap Release and Assessing the Pharmacology of Antagonists
Published on: October 18, 2024
07:05Visualization of Neutrophil Extracellular Traps in Mesenteric Venules After Mesenteric Ischemia-Reperfusion Injury via Intravital Microscopy
Published on: September 27, 2024
